AMLX Valuation

Amylyx Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

9.300

+0.87(10.320%)1D

Overview
Forecast
Valuation
Earnings

AMLX Relative Valuation

AMLX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AMLX is overvalued; if below, it's undervalued.

Historical Valuation

Amylyx Pharmaceuticals Inc (AMLX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 1.81. The fair price of Amylyx Pharmaceuticals Inc (AMLX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：9.21

Fair

-5.00

Trailing

Forward

-3.20

EV/EBITDA

Amylyx Pharmaceuticals Inc. (AMLX) has a current EV/EBITDA of -3.20. The 5-year average EV/EBITDA is 2.53. The thresholds are as follows: Strongly Undervalued below -21.92, Undervalued between -21.92 and -9.69, Fairly Valued between 14.75 and -9.69, Overvalued between 14.75 and 26.98, and Strongly Overvalued above 26.98. The current Forward EV/EBITDA of -3.20 falls within the Historic Trend Line -Fairly Valued range.

-2.89

EV/EBIT

Amylyx Pharmaceuticals Inc. (AMLX) has a current EV/EBIT of -2.89. The 5-year average EV/EBIT is 2.94. The thresholds are as follows: Strongly Undervalued below -21.43, Undervalued between -21.43 and -9.24, Fairly Valued between 15.13 and -9.24, Overvalued between 15.13 and 27.31, and Strongly Overvalued above 27.31. The current Forward EV/EBIT of -2.89 falls within the Historic Trend Line -Fairly Valued range.

0.00

Amylyx Pharmaceuticals Inc. (AMLX) has a current PS of 0.00. The 5-year average PS is 698.01. The thresholds are as follows: Strongly Undervalued below -5646.06, Undervalued between -5646.06 and -2474.03, Fairly Valued between 3870.05 and -2474.03, Overvalued between 3870.05 and 7042.08, and Strongly Overvalued above 7042.08. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Amylyx Pharmaceuticals Inc. (AMLX) has a current P/OCF of 0.00. The 5-year average P/OCF is 1.53. The thresholds are as follows: Strongly Undervalued below -10.20, Undervalued between -10.20 and -4.34, Fairly Valued between 7.40 and -4.34, Overvalued between 7.40 and 13.27, and Strongly Overvalued above 13.27. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-4.59

P/FCF

Amylyx Pharmaceuticals Inc. (AMLX) has a current P/FCF of -4.59. The 5-year average P/FCF is 7.92. The thresholds are as follows: Strongly Undervalued below -43.97, Undervalued between -43.97 and -18.02, Fairly Valued between 33.87 and -18.02, Overvalued between 33.87 and 59.81, and Strongly Overvalued above 59.81. The current Forward P/FCF of -4.59 falls within the Historic Trend Line -Fairly Valued range.

Amylyx Pharmaceuticals Inc (AMLX) has a current Price-to-Book (P/B) ratio of 4.26. Compared to its 3-year average P/B ratio of 3.88 , the current P/B ratio is approximately 9.97% higher. Relative to its 5-year average P/B ratio of 3.64, the current P/B ratio is about 17.32% higher. Amylyx Pharmaceuticals Inc (AMLX) has a Forward Free Cash Flow (FCF) yield of approximately -28.95%. Compared to its 3-year average FCF yield of -18.83%, the current FCF yield is approximately 53.79% lower. Relative to its 5-year average FCF yield of -17.50% , the current FCF yield is about 65.46% lower.

4.48

P/B

Median3y

3.88

Median5y

3.64

-28.20

FCF Yield

Median3y

-18.83

Median5y

-17.50

Competitors Valuation Multiple

The average P/S ratio for AMLX's competitors is 2.11, providing a benchmark for relative valuation. Amylyx Pharmaceuticals Inc Corp (AMLX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AMLX.O

Amylyx Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

Phathom Pharmaceuticals Inc

Mind Medicine (MindMed) Inc

Loss

775.34M

DAWN.O

Day One Biopharmaceuticals Inc

Performance Decomposition

Market capitalization of AMLX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of AMLX in the past 1 year is driven by Unknown.